Anti-Adenine Nucleotide Translocase 1/ANT 1 antibody (ab221956)
Key features and details
- Rabbit polyclonal to Adenine Nucleotide Translocase 1/ANT 1
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-Adenine Nucleotide Translocase 1/ANT 1 antibody
See all Adenine Nucleotide Translocase 1/ANT 1 primary antibodies -
Description
Rabbit polyclonal to Adenine Nucleotide Translocase 1/ANT 1 -
Host species
Rabbit -
Specificity
This antibody is named based on homology. It can also recognise ADP/ATP translocase 2, SLC25A31, SLC25A5 and SLC25A6 due to homology of 93% in immunogen sequence.
-
Tested applications
Suitable for: IHC-P, WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Rabbit, Cow
-
Immunogen
Recombinant fragment corresponding to Human Adenine Nucleotide Translocase 1/ANT 1 aa 19-46.
Sequence:AAVSKTAVAPIERVKLLLQVQHASKQIS
Database link: P12235 -
Positive control
- IHC-P: Human cerebellum, kidney and duodenum tissue. WB: RT-4 and U-251 MG cell lysate.
-
General notes
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.02% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), PBS -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab221956 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P | 1/20 - 1/50. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. | |
| WB | Use a concentration of 0.04 - 0.4 µg/ml. Predicted molecular weight: 33 kDa. |
Target
-
Function
Catalyzes the exchange of ADP and ATP across the mitochondrial inner membrane. -
Involvement in disease
Defects in SLC25A4 are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions autosomal dominant type 2 (PEOA2) [MIM:609283]. Progressive external ophthalmoplegia is characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism. -
Sequence similarities
Belongs to the mitochondrial carrier family.
Contains 3 Solcar repeats. -
Cellular localization
Mitochondrion inner membrane. - Information by UniProt
-
Database links
- Entrez Gene: 282478 Cow
- Entrez Gene: 291 Human
- Entrez Gene: 11739 Mouse
- Entrez Gene: 85333 Rat
- Omim: 103220 Human
- SwissProt: P02722 Cow
- SwissProt: P12235 Human
- SwissProt: P48962 Mouse
see all -
Alternative names
- AAC1 antibody
- Adenine Nucleotide Translocase 1 antibody
- Adenine nucleotide translocator 1 (skeletal muscle) antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Adenine Nucleotide Translocase 1/ANT 1 antibody (ab221956)
Paraffin embedded human cerebellum tissue stained for Adenine Nucleotide Translocase 1/ANT 1 with ab221956 (1/20 dilution) in immunohistochemical analysis.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Adenine Nucleotide Translocase 1/ANT 1 antibody (ab221956)Paraffin embedded human kidney tissue stained for Adenine Nucleotide Translocase 1/ANT 1 with ab221956 (1/20 dilution) in immunohistochemical analysis.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Adenine Nucleotide Translocase 1/ANT 1 antibody (ab221956)Paraffin embedded human duodenum tissue stained for Adenine Nucleotide Translocase 1/ANT 1 with ab221956 (1/20 dilution) in immunohistochemical analysis.
-
Western blot - Anti-Adenine Nucleotide Translocase 1/ANT 1 antibody (ab221956)All lanes : Anti-Adenine Nucleotide Translocase 1/ANT 1 antibody (ab221956) at 1/100 dilution
Lane 1 : RT-4 cell lysate
Lane 2 : U-251 MG cell lysate
Predicted band size: 33 kDa
Protocols
Datasheets and documents
References (0)
ab221956 has not yet been referenced specifically in any publications.
